Sanofi and Regeneron last week released promising phase III trial data for...

...its drug Libtayo, which shows that the PD-1/PD-L1 inhibitor can extend the lives of patients battling non-small cell lung cancer (NSCLC). The companies say they will submit the new data to the FDA for approval this year. Among the most advantaged systemic therapies for NSCLC are Eli Lilly’s Alimta, Celgene's Abraxane and Merck's oncology behemoth Keytruda. Libtayo is currently FDA-approved for the treatment of cutaneous squamous cell carcinoma, and holds preferred formulary status for 9% of covered lives, growing to 11% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 4/29/20